Wegovy for Weight Loss: Complete Guide for Women

Disclosure: This page contains affiliate links. We may earn a commission if you purchase through our links, at no extra cost to you.

Wegovy for Weight Loss: Complete Guide for Women

Wegovy (semaglutide 2.4 mg) is an FDA-approved prescription medication for chronic weight management. It is the same active ingredient as Ozempic but at a higher dose specifically approved for weight loss rather than blood sugar management. Clinical trials show an average of 15 to 17% body weight reduction over 68 weeks, which represents a meaningful step beyond what most lifestyle interventions alone can achieve.

This guide covers how Wegovy works, what women specifically should know, cost and access options, what to expect during treatment, and how it compares to the broader GLP-1 medication landscape.

Wegovy was the medication that finally worked for me after years of programs that worked only as long as I was actively fighting my own hunger. Based on my research and my own experience, I would start with what to expect physically, which I cover in Wegovy side effects in women, and what it actually costs, covered in how much Wegovy costs. If you are trying to decide between Wegovy and Ozempic specifically, I laid that comparison out in Ozempic vs. Wegovy. This is not medical advice, but here is what to ask your doctor before you start, and it helped me to understand the hormonal mechanism first, which I explain more in GLP-1 for weight loss.

Key Takeaways

  • Wegovy is semaglutide 2.4 mg, FDA-approved specifically for chronic weight management since June 2021
  • Clinical trials show average weight loss of 15 to 17% of body weight over 68 weeks
  • It works by mimicking GLP-1, a gut hormone that slows digestion, signals satiety, and improves insulin sensitivity
  • Women in the clinical trials lost an average of 16.9% of body weight, with 83% losing at least 5% of body weight
  • The most common side effects are gastrointestinal and are manageable with gradual dose escalation
  • Telehealth platforms have made Wegovy and compounded semaglutide significantly more accessible without in-person clinic visits

How Wegovy Works

GLP-1 (glucagon-like peptide-1) is a hormone released by the gut after eating. It signals the pancreas to release insulin, tells the brain that the stomach is full, and slows the rate at which food moves through the digestive system. In people with obesity or metabolic dysfunction, GLP-1 signaling is often blunted, meaning the brain does not receive adequate satiety signals even when calorie intake is sufficient.

Semaglutide, the active ingredient in Wegovy, is a synthetic GLP-1 analog. It binds to GLP-1 receptors throughout the body, producing effects that last far longer than the natural hormone. Weekly injections maintain persistent GLP-1 receptor activation, creating a sustained reduction in appetite, slowing of gastric emptying, and improvement in insulin sensitivity throughout the week.

The result is that hunger feels lower, fullness comes earlier, cravings for high-calorie foods decrease, and blood sugar regulation improves. For women with insulin resistance (which worsens significantly during perimenopause and menopause), the metabolic improvement compounds the weight loss benefit.

Wegovy Dosing Schedule

Wegovy is started at a low dose and escalated gradually over 16 weeks to minimize gastrointestinal side effects.

  • Weeks 1 to 4: 0.25 mg weekly
  • Weeks 5 to 8: 0.5 mg weekly
  • Weeks 9 to 12: 1.0 mg weekly
  • Weeks 13 to 16: 1.7 mg weekly
  • Week 17 onward: 2.4 mg weekly (maintenance dose)

Some patients remain at an intermediate dose if the 2.4 mg dose is not tolerated. The dose escalation schedule is designed to allow the gut to adapt and minimize nausea and discomfort.

Wegovy Results: What the Clinical Trials Show

The STEP clinical trial program studied Wegovy across multiple populations. The most relevant trial for women seeking weight loss (STEP 1) included over 1,900 adults with obesity or overweight with weight-related health conditions.

  • Average weight loss at 68 weeks: 14.9% of body weight on Wegovy vs. 2.4% on placebo
  • 83% of Wegovy participants lost at least 5% of body weight
  • 69% lost at least 10% of body weight
  • 50% lost at least 15% of body weight
  • 30% lost more than 20% of body weight

In practical terms, a woman starting at 200 pounds could expect to lose 25 to 35 pounds on average over 16 months, with some losing significantly more.

Wegovy vs. Ozempic: What Is the Difference?

Both Wegovy and Ozempic contain semaglutide. The key differences are dose and FDA approval indication.

  • Ozempic (0.5 to 2.0 mg) is FDA-approved for type 2 diabetes management
  • Wegovy (2.4 mg) is FDA-approved specifically for chronic weight management
  • Both work the same way; the higher dose in Wegovy produces greater weight loss
  • Ozempic is sometimes prescribed off-label for weight loss when Wegovy is unavailable

Wegovy vs. Compounded Semaglutide

Due to Wegovy shortages and high cost, compounded semaglutide has become a widely used alternative. Compounded versions contain the same active ingredient at equivalent doses but are produced by licensed compounding pharmacies rather than Novo Nordisk. They are typically 50 to 80% less expensive than brand-name Wegovy.

Telehealth platforms like ShedRX provide access to licensed prescribers who can evaluate candidacy for both brand-name Wegovy and compounded semaglutide, managing the entire treatment process online. This has significantly reduced the barrier to access for women who do not have an obesity medicine specialist nearby.

Who Qualifies for Wegovy

FDA criteria for Wegovy eligibility:

  • BMI of 30 or higher, OR
  • BMI of 27 or higher with at least one weight-related health condition (type 2 diabetes, high blood pressure, high cholesterol, sleep apnea)

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or a history of pancreatitis. A telehealth evaluation will screen for these conditions.

Getting Wegovy Online

As of 2025, telehealth access to semaglutide is well-established. The process typically involves completing a health history intake, a clinician review of your information, and a prescription sent to a pharmacy or compounding provider if you qualify.

ShedRX specializes in GLP-1 and metabolic health programs, with licensed prescribers experienced in managing menopausal and perimenopausal patients. GobyMeds is another telehealth provider offering GLP-1 therapy evaluation with straightforward online access.

Posts in This Cluster

Frequently Asked Questions

Is Wegovy safe for women?

Wegovy has been studied extensively in large clinical trials including significant numbers of women. The safety profile is well-characterized. The most common side effects are gastrointestinal (nausea, vomiting, diarrhea) and are typically manageable with slow dose escalation. Wegovy is not recommended during pregnancy or breastfeeding.

How much weight can a woman expect to lose on Wegovy?

Clinical trial data shows an average of 15 to 17% of body weight over 68 weeks. For a 180-pound woman, that is approximately 27 to 30 pounds. Results vary by individual, adherence to dose escalation, and lifestyle factors. Women who combine Wegovy with protein-forward eating and strength training tend to see better results and preserve more muscle mass.

Does Wegovy work for menopausal weight gain?

Yes. The insulin resistance and appetite dysregulation that Wegovy addresses are exactly the mechanisms worsened during menopause. Many clinicians find menopausal women respond well to GLP-1 therapy, particularly for visceral fat reduction, because it directly targets the metabolic disruption that makes menopausal weight loss so difficult.

How long do you have to take Wegovy?

Wegovy is intended for long-term use. Clinical data shows that patients who discontinue the medication regain most of the lost weight within one to two years. This reflects that obesity is a chronic condition requiring ongoing management, not a short-term intervention. Many patients remain on Wegovy or a maintenance dose of semaglutide long-term.

What is the cheapest way to get Wegovy?

Brand-name Wegovy costs approximately $1,300 per month without insurance. Novo Nordisk’s savings program reduces cost to around $650 per month for eligible commercially insured patients. Compounded semaglutide through telehealth providers costs $100 to $400 per month depending on the provider and dose. ShedRX and GobyMeds are among the more cost-accessible telehealth options.

Privacy Policy - Terms and Conditions